David A. Fiellin, MD
Associate Professor of Medicine
Yale University School of Medicine
David A. Fiellin, M.D. is an Associate Professor of Medicine at Yale University School of Medicine. Dr. Fiellin graduated from Earlham College and Emory University School of Medicine. After completing his residency and chief residency at Yale, Dr. Fiellin stayed at Yale to enter The Robert Wood Johnson Clinical Scholars Program.  He joined the faculty at Yale in 1997.  Currently, Dr. Fiellin practices general internal medicine, conducts research and teaches.  Dr. Fiellin has focused his scholarly work on the interface between primary care and substance abuse. He conducts research on the transfer of treatment strategies, including opioid agonist maintenance with methadone and buprenorphine, from specialized settings to office-based, primary care and HIV specialty settings. He has directed trials investigating the efficacy of office-based prescribing of methadone and buprenorphine in primary care and HIV specialty settings.  He is Medical Director, of the SAMHSA Physician Clinical Support System for buprenorphine and Co-Chair of the Society of General Internal Medicine’s Substance Abuse Task Force.  He has served on the Office of National Drug Control Policy (ONDCP), Drug Control Research, Data, and Evaluation Advisory Committee, and serves on the World Health Organization and United Nations Office on Drugs and Crime Technical Guideline Development Group for psychosocially assisted pharmacologic treatment of opioid dependence. He serves on the Editorial Boards of Substance Abuse and the Journal of Addiction Medicine and is Co-Editor of Alcohol, Other Drugs & Health: Current Evidence and the Principles of Addiction Medicine, 4th Edition.